



**Editor**  
Tore K Kvien

**Associate Editors**

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 10.377

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Teichset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

**Editorial**

**321** Targeting BAFF/BlyS in lupus: is the glass half-full or half-empty?  
*F A Houssiau, A Doria*

**Clinical and epidemiological research**

**323** Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study  
*D A Isenberg, M Petri, K Kalunian, Y Tanaka, M B Urowitz, R W Hoffman, M Morgan-Cox, N Ikuni, M Silk, D J Wallace*

**332** Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study  
*J T Merrill, R F van Vollenhoven, J P Buyon, R A Furie, W Stohl, M Morgan-Cox, C Dickson, P W Anderson, C Lee, P-Y Berclaz, T Dörner*

**341** Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration  
*I Navarro-Millán, S Yang, S L DuVall, L Chen, J Baddley, G W Cannon, E S Delzell, J Zhang, M M Safford, N M Patkar, T R Mikuls, J A Singh, J R Curtis*

**348** Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients  
*P Brito-Zerón, B Kostov, R Solans, G Fraile, C Suárez-Cuervo, A Casanovas, F J Rascón, R Qanneta, R Pérez-Alvarez, M Ripoll, M Akasbi, B Pinilla, J A Bosch, J Nava-Mateos, B Díaz-López, M L Morera-Morales, H Gheitis, S Retamozo, M Ramos-Casals, on behalf of the SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEM)*

**356** Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial  
*A Kastbom, K Forslind, S Ernestam, P Geborek, J A Karlsson, I F Petersson, S Saevastdotiir, L Klareskog, R F van Vollenhoven, K Lundberg*

**362** Suitability of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment  
*L R Ranganath, A M Milan, A T Hughes, J J Dutton, R Fitzgerald, M C Briggs, H Bygott, E E Psarelli, T F Cox, J A Gallagher, J C Jarvis, C van Kan, A K Hall, D Laan, B Olsson, J Szamosi, M Rudebeck, T Kullenberg, A Cronlund, L Svensson, C Junestrand, H Ayoub, O G Timmis, N Sireau, K-H Le Quan Sang, F Genovesi, D Braconi, A Santucci, M Nemethova, A Zatkova, J McCaffrey, P Christensen, G Ross, R Imrich, J Rovinsky*

**368** The offspring of people with a total knee replacement for severe primary knee osteoarthritis have a higher risk of worsening knee pain over 8 years  
*F Pan, C Ding, T Winzenberg, H Khan, J Martel-Pelletier, J-P Pelletier, F Cicuttini, G Jones*

**374** Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis  
*D P Tashkin, E R Volkman, C-H Tseng, H J Kim, J Goldin, P Clements, D Furst, D Khanna, E Kleerup, M D Roth, R Elashoff*

**382** Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)  
*R Seror, H Bootsma, A Saraux, S J Bowman, E Theander, J G Brun, G Baron, V Le Guern, V Devauchelle-Pensec, M Ramos-Casals, V Valim, T Dörner, A Tzioufas, J-E Gottenberg, R S Laqué, T Manal, E Hachulla, K L Sivils, W-F Ng, A-L Fauchais, S Bombardieri, R Priori, E Bartoloni, V Goeb, S Praprotnik, T Sumida, S Nishiyama, R Caporali, A A Kruize, C Vollenweider, P Ravaut, P Meiners, P Brito-Zerón, C Vitali, X Mariette, on behalf of the EULAR Sjögren's Task Force*

**390** Synovitis in knee osteoarthritis: a precursor of disease?  
*I Aukoralta, C K Kwok, A Guermazi, F W Roemer, R M Boudreau, M J Hannon, D J Hunter*

**396** Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss)  
*A J Mohammad, A Hot, F Arndt, F Moosig, M-J Guerry, N Amudala, R Smith, P Sivasothy, L Guillevin, P A Merkel, D R W Jayne*

**402** Global ultrasound assessment of structural lesions in osteoarthritis: a reliability study by the OMERACT ultrasonography group on scoring cartilage and osteophytes in finger joints  
*H B Hammer, A Iagnocco, A Mathiessen, E Filippucci, F Gandjbakch, M C Kortekaas, I Möller, E Naredo, R J Wakefield, P Aegerter, M-A D'Agostino*

**408** Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study  
*X Baraliakos, B Borah, J Braun, D Baeten, D Laurent, J Sieper, P Emery, I B McInnes, J M van Laar, P Wordsworth, J Wollenhaupt, H Kellner, L Colin, F Vandenheide, K Radford, W Hueber*

**MORE CONTENTS ►**



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



The online version of this article contains multiple choice questions hosted on BMJ Learning.

**Basic and translational research**

- 413** Rsk2 controls synovial fibroblast hyperplasia and the course of arthritis  
*A Derer, C Böhm, B Grötsch, J R Grün, A Grützkeu, M Stock, S Böhm, B Sehnert, U Gaipl, G Scheit, A J Hueber, J-P David*
- 422** The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts  
*K Klein, P A Kabala, A M Grabiec, R E Gay, C Kolling, L-L Lin, S Gay, P P Tak, R K Pinjha, C Ospelt, K A Reedquist*
- 430** Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression  
*C Angiolilli, A M Grabiec, B S Ferguson, C Ospelt, B M Fernandez, I E van Es, L G M van Baarsen, S Gay, T A McKinsey, P P Tak, D L Baeten, K A Reedquist*
- 439** Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation  
*C C Thornton, F Al-Rashed, D Calay, G M Birdsey, A Bauer, H Mylroie, B J Morley, A M Randi, D O Haskard, J J Boyle, J C Mason*
- 449** Oxidative changes and signalling pathways are pivotal in initiating age-related changes in articular cartilage  
*W Hui, D A Young, A D Rowan, X Xu, T E Cawston, C J Proctor*
- 459** A circulating reservoir of pathogenic-like CD4<sup>+</sup> T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment  
*R Spreafico, M Rossetti, J van Loosdregt, C A Wallace, M Massa, S Magni-Manzoni, M Gattorno, A Martini, D J Lovell, S Albani*

**466** IL-6-driven STAT signalling in circulating CD4<sup>+</sup> lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis  
*A E Anderson, A G Pratt, M A K Sedhom, J P Doran, C Routledge, B Hargreaves, P M Brown, K-A Lê Cao, J D Isaacs, R Thomas*

**474** Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice  
*M Manetti, I Rosa, M Fazi, S Guiducci, P Carmeliet, L Ibba-Manneschi, M Matucci-Cerinic*

**Correction**

**473** Correction

**Electronic pages****Correspondence**

**e10** From BLISS to ILLUMINATE studies: "Blys repetita placent"?  
*L Chiche, N Jourde-Chiche, F Retornaz, D Cornec*

**e11** Further thoughts about the ILLUMINATE studies of tabalumab in SLE  
*D Isenberg*

**Thank you to our reviewers**

**e12** Thank you to our reviewers 2015